Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Bardia, A; Hurvitz, SA; Tolaney, SM; Loirat, D; Punie, K; Oliveira, M; Brufsky, A; Sardesai, SD; Kalinsky, K; Zelnak, AB; Weaver, R; Traina, T; Dalenc, F; Aftimos, P; Lynce, F; Diab, S; Cortes, J; O'Shaughnessy, J; Dieras, V; Ferrario, C; Schmid, P; Carey, LA; Gianni, L; Piccart, MJ; Loibl, S; Goldenberg, DM; Hong, Q; Olivo, MS; Itri, LM; Rugo, HS

Bardia, A (corresponding author), Massachusetts Gen Hosp, Canc Ctr, BHX 237,55 Fruit St, Boston, MA 02114 USA.

NEW ENGLAND JOURNAL OF MEDICINE, 2021; 384 (16): 1529

Abstract

Background Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索